EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination

Hugo C Turner, Klodeta Kura, Barbara Roth, Annette C Kuesel, Sally Kinrade, Maria-Gloria Basáñez iD

Clinical Infectious Diseases · 25.04.2024 · 78 (Supplement_2) · S138-S145

DOI: 10.1093/cid/ciae054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.04.2024. Verfasst von Hugo C Turner und 5 weiteren Autor:innen. Beteiligte Einrichtung: UK Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Im…. Hauptthemen laut MEDLINE: Macrolides, Onchocerciasis, Ivermectin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Gates Foundation, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concerns that annual mass administration of ivermectin, the predominant strategy for onchocerciasis control and elimination, may not lead to elimination of parasite transmission (EoT) in all endemic areas have increased interest in alternative treatment strategies. One such strategy is moxidectin. We performed an updated economic assessment of moxidectin- relative to ivermectin-based strategies.

Methods

We investigated annual and biannual community-directed treatment with ivermectin (aCDTI, bCDTI) and moxidectin (aCDTM, bCDTM) with minimal or enhanced coverage (65% or 80% of total population taking the drug, respectively) in intervention-naive areas with 30%, 50%, or 70% microfilarial baseline prevalence (representative of hypo-, meso-, and hyperendemic areas). We compared programmatic delivery costs for the number of treatments achieving 90% probability of EoT (EoT90), calculated with the individual-based stochastic transmission model EPIONCHO-IBM. We used the costs for 40 years of program delivery when EoT90 was not reached earlier. The delivery costs do not include drug costs. Results aCDTM and bCDTM achieved EoT90 with lower programmatic delivery costs than aCDTI with 1 exception: aCDTM with minimal coverage did not achieve EoT90 in hyperendemic areas within 40 years. With minimal coverage, bCDTI delivery costs as much or more than aCDTM and bCDTM. With enhanced coverage, programmatic delivery costs for aCDTM and bCDTM were lower than for aCDTI and bCDTI.

Conclusions

Moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. The costs of moxidectin to national programs are needed to quantify whether delivery cost reductions will translate into overall program cost reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrolidesOnchocerciasisIvermectinHumansMass Drug AdministrationDisease EradicationCost-Benefit Analysis

Stichwörter der Autor:innen

economic assessmenteliminationivermectinmoxidectinonchocerciasis

Substanzen

moxidectinMacrolidesIvermectin

Autor:innen und Institutionen

  • UK Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.
  • London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.
  • Medicines Development for Global Health, Melbourne, Victoria, Australia.
  • UNICEF/United Nations Development Progamme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland (retired).

ORCID-Profile: Maria-Gloria Basáñez

Förderung

  • World Health Organization
  • Gates Foundation
  • Medical Research Council
  • Medicines Development for Global Health
  • Bill & Melinda Gates Foundation

Zitieren

APA

Turner, H. C., Kura, K., Roth, B., Kuesel, A. C., Kinrade, S., & Basáñez, M. G. (2024). An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination. Clinical Infectious Diseases, 78(Supplement_2), S138-S145. https://doi.org/10.1093/cid/ciae054

Vancouver

Turner HC, Kura K, Roth B, Kuesel AC, Kinrade S, Basáñez MG. An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination. Clinical Infectious Diseases. 2024;78(Supplement_2):S138-S145. doi:10.1093/cid/ciae054

BibTeX
@article{Turner2024,
  author = {Turner, Hugo C and Kura, Klodeta and Roth, Barbara and Kuesel, Annette C and Kinrade, Sally and Basáñez, Maria-Gloria},
  title = {An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {Supplement_2},
  pages = {S138--S145},
  doi = {10.1093/cid/ciae054}
}
Kostenlos starten →